Article
Pharmacology & Pharmacy
Sophia J. Tate, Leen van de Sande, Wim P. Ceelen, Jared Torkington, Alan L. Parker
Summary: This study evaluated the feasibility and tolerance of pressurised intraperitoneal aerosolised virotherapy (PIPAV) for delivering oncolytic adenoviruses. Results showed that adenoviruses retained viability and transduction efficacy after pressurised aerosolisation in vitro. In vivo experiments in rats demonstrated good tolerability of PIPAV, although further optimization is needed for improved efficacy in vivo.
Review
Oncology
Ke-Tao Jin, Wen-Lin Du, Yu-Yao Liu, Huan-Rong Lan, Jing-Xing Si, Xiao-Zhou Mou
Summary: Oncolytic virotherapy is a promising approach in cancer immunotherapy that aims to provoke antitumor immune response in the tumor microenvironment, enhancing the effects of other immunotherapies. The reciprocal interaction between oncolytic viruses and TME is a hot topic for investigators to improve OVT efficacy and reduce off-target adverse events.
Article
Immunology
Mohsen Keshavarz, Seyed Mohammad Miri, Emad Behboudi, Yaser Arjeini, Hassan Dianat-Moghadam, Amir Ghaemi
Summary: This paper summarizes the latest advancements in the use of chemical and biological compounds for safe and efficient delivery of oncolytic viruses to target tissues or tumor deposits.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2022)
Review
Oncology
Liting Chen, Zhijun Ma, Chen Xu, Youbang Xie, Defang Ouyang, Shuhui Song, Xiao Zhao, Funan Liu
Summary: Oncolytic virus (OV) therapy is a critical component of tumor immunotherapy. By modifying OVs with nanomaterials, their toxicity can be reduced and safety can be increased, expanding their clinical applications.
CANCER BIOLOGY & MEDICINE
(2023)
Article
Cell Biology
Joao Santos, Camilla Heinio, Dafne Quixabeira, Sadia Zafar, James Clubb, Santeri Pakola, Victor Cervera-Carrascon, Riikka Havunen, Anna Kanerva, Akseli Hemminki
Summary: Immunotherapy using tumor-infiltrating lymphocytes (TIL) or oncolytic adenoviruses has shown promising results in cancer treatment. When used in combination, the antitumor effect is synergistically potentiated. Studies suggest that by incubating oncolytic adenovirus with TILs prior to systemic injection, the virus can be efficiently delivered to tumors, enhancing therapeutic efficacy.
Article
Chemistry, Multidisciplinary
Mingyang Liu, Ruizhe Zhang, Hanwei Huang, Pengfei Liu, Xu Zhao, Hu Wu, Ying He, Ruizhe Xu, Xifeng Qin, Zhenguo Cheng, Hongyu Liu, Onder Ergonul, Fusun Can, Defang Ouyang, Zhenning Wang, Zhiqing Pang, Funan Liu
Summary: A simple and efficient strategy of erythrocyte-leveraged oncolytic virotherapy (ELeOVt) is reported, which assembles oncolytic viruses (OVs) on the surface of erythrocytes with near 100% efficiency and achieves targeted delivery to the lungs, significantly improving the treatment of pulmonary metastases while reducing toxicity.
Article
Chemistry, Multidisciplinary
Qing Wu, Hanwei Huang, Mengchi Sun, Ruizhe Zhang, Junxia Wang, Hanqi Zheng, Chaojie Zhu, Shihua Yang, Xinyuan Shen, Jiaqi Shi, Feng Liu, Wei Wu, Jin Sun, Funan Liu, Hongjun Li, Zhen Gu
Summary: This study describes a virus-concealed tumor-targeting strategy that enables the delivery of oncolytic viruses (OVs) to lung metastasis through systemic administration. The OVs can actively infect, be internalized, and cloak into tumor cells, which are subsequently treated to eliminate their pathogenicity. This Trojan Horse-like vehicle avoids virus neutralization and clearance in the bloodstream and facilitates tumor-targeted delivery with over 110-fold virus enrichment. Additionally, this strategy can function as a tumor vaccine and initiate endogenous adaptive antitumor effects by increasing memory T cells and modulating the tumor immune microenvironment.
ADVANCED MATERIALS
(2023)
Review
Cell Biology
Ludi Yang, Xiang Gu, Jie Yu, Shengfang Ge, Xianqun Fan
Summary: Oncolytic viruses, either natural or genetically engineered, can replicate in tumor cells and inhibit tumor growth, making them an effective anticancer strategy. Their multifunctional characteristics suggest promising application prospects in cancer therapeutics.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Review
Immunology
Jiayi Zeng, Xiangxue Li, Max Sander, Haipeng Zhang, Guangmei Yan, Yuan Lin
Summary: The prognosis of malignant gliomas remains poor, with limited therapeutic options. Immunotherapy and oncolytic virotherapy are rapidly developing fields that hold promise for enhancing cancer treatment effectiveness.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Oncology
Dennis Doleschel, Sabine Hoff, Susanne Koletnik, Anne Rix, Dieter Zopf, Fabian Kiessling, Wiltrud Lederle
Summary: The study showed that the combination therapy of REG and aPD1 significantly improved anti-tumor activity in both colorectal cancer models. The synergistic effects of the two drugs induced sustained M1 polarization and durable reduction of Treg cells, leading to a sustained inhibition of colon cancer regrowth. This suggests the potential for clinical evaluation in colorectal cancer, including MSS tumors.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2021)
Review
Immunology
Qingbo Li, Fengxian Tan, Yuanyuan Wang, Xiaohui Liu, Xianbin Kong, Jingyan Meng, Long Yang, Shan Cen
Summary: This review focuses on the regulatory mechanisms of interferons (IFNs) by various oncolytic viruses and their combination therapies. Understanding these mechanisms is of great significance for improving the antitumor effect of oncolytic viruses.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Medicine, Research & Experimental
Yingping Zeng, Shufen Zhang, Sufen Li, Guangtao Song, Tingting Meng, Hong Yuan, Fuqiang Hu
Summary: Abnormal tumor blood vessels with high leakage can enhance tumor metastasis. Normalizing tumor blood vessels can reduce leakage and increase integrity. This study developed multifunctional nanoparticles combining chemotherapy and tumor blood vessel normalization for breast cancer treatment. The nanoparticles promoted expression of junction proteins in endothelial cells, protected endothelial cell layer integrity, and inhibited tumor cell migration and metastasis.
MOLECULAR PHARMACEUTICS
(2023)
Review
Oncology
Rui Ma, Zhenlong Li, E. Antonio Chiocca, Michael A. Caligiuri, Jianhua Yu
Summary: Oncolytic viruses offer potential as a novel therapy for cancer patients resistant to traditional treatments. They can directly kill tumor cells and activate an immune response, while sparing normal cells. However, challenges such as limited tumor penetration, short persistence, and the host immune response hinder the clinical translation of oncolytic virotherapy. Overcoming these challenges could lead to powerful combination therapies, such as oncolytic viruses plus immune checkpoint blockade or CAR-based immunotherapies.
Review
Immunology
Qingbo Li, Patrick Kwabena Oduro, Rui Guo, Ruiqiao Li, Ling Leng, Xianbin Kong, Qilong Wang, Long Yang
Summary: Oncolytic virus therapy is a rapidly advancing approach for treating malignant tumors, with high specificity and safety. The treatment of malignant tumors in the digestive system still requires improvement, and oncolytic viruses may provide therapeutic solutions for this issue.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
(2022)
Review
Neurosciences
Zhongbing Qi, Xiangyu Long, Jiyan Liu, Ping Cheng
Summary: Glioblastoma is a highly aggressive form of brain tumor that responds poorly to conventional therapies. Oncolytic virus therapy shows promise in improving therapeutic efficacy, but limitations as a monotherapy need to be overcome.
FRONTIERS IN CELLULAR NEUROSCIENCE
(2022)
Article
Oncology
Amy Kwan, Natalie Winder, Emer Atkinson, Haider Al-Janabi, Richard J. Allen, Russell Hughes, Mohammed Moamin, Rikah Louie, Dhanajay Evans, Matthew Hutchinson, Drew Capper, Katie Cox, Joshua Handley, Adam Wilshaw, Taewoo Kim, Simon J. Tazzyman, Sanjay Srivastava, Penelope Ottewell, Jayakumar Vadakekolathu, Graham Pockley, Claire E. Lewis, Janet E. Brown, Sarah J. Danson, Joe Conner, Munitta Muthana
Summary: This study demonstrates that oncolytic virus HSV1716 can activate the antitumor functions of immune cells and reprogram tumor-associated macrophages to a less immunosuppressive phenotype. HSV1716 administration led to marked tumor shrinkage in primary mammary tumors and a decrease in metastases, associated with increased recruitment/activation of cytotoxic T cells and a reduction in regulatory T cells.
MOLECULAR CANCER THERAPEUTICS
(2021)
Article
Chemistry, Multidisciplinary
Siyuan Deng, Alessandra Iscaro, Giorgia Zambito, Yimin Mijiti, Marco Minicucci, Magnus Essand, Clemens Lowik, Munitta Muthana, Roberta Censi, Laura Mezzanotte, Piera Di Martino
Summary: A redox responsive nanohydrogel based on hyaluronic acid was developed as a delivery system for oncolytic viruses, showing rapid degradation in a reductive environment and good oncolytic activity. Due to its hydrophilic and porous nature, the nanohydrogel is considered a promising carrier for viral drugs.
Article
Pharmacology & Pharmacy
Zainab Taher, Christopher Legge, Natalie Winder, Pawel Lysyganicz, Andrea Rawlings, Helen Bryant, Munitta Muthana, Sarah Staniland
Summary: This study compared magnetosomes and coated MNP of different sizes, finding that coated MNP can be effectively taken up by cancer cells and show similar effects to magnetosomes. Size of MNP does not significantly affect cancer cell uptake. Surface functionalization of magnetosomes and silica-coated MNP allows for modification to facilitate uptake by cancer cells.
Article
Cardiac & Cardiovascular Systems
Evelina Vagesjo, Kristel Parv, David Ahl, Cedric Seignez, Carmen Herrera Hidalgo, Antoine Giraud, Catarina Leite, Olle Korsgren, Hakan Wallen, Greta Juusola, Harri H. Hakovirta, Helene Rundqvist, Magnus Essand, Lena Holm, Randall S. Johnson, Charlotte Thalin, Petra Korpisalo, Gustaf Christoffersson, Mia Phillipson
Summary: This study reveals a novel role of macrophages in regulating blood flow by releasing iNOS in ischemic muscles to improve tissue perfusion and repair. Depletion of iNOS in macrophages compromised blood flow regulation and exacerbated ischemic damage in the muscles.
CIRCULATION RESEARCH
(2021)
Review
Virology
Amy Kwan, Natalie Winder, Munitta Muthana
Summary: Oncolytic virotherapy is a promising immunotherapeutic approach for breast cancer, with the potential to overcome the immunogenic cold nature of the tumor. While pre-clinical studies have shown promise, the challenges of monotherapy limitations and specific barriers in the breast cancer population need to be addressed for successful clinical trials.
Article
Multidisciplinary Sciences
Luuk van Hooren, Alessandra Vaccaro, Mohanraj Ramachandran, Konstantinos Vazaios, Sylwia Libard, Tiarne van de Walle, Maria Georganaki, Hua Huang, Ilkka Pietilae, Joey Lau, Maria H. Ulvmar, Mikael C. I. Karlsson, Maria Zetterling, Sara M. Mangsbo, Asgeir S. Jakola, Thomas Olsson Bontell, Anja Smits, Magnus Essand, Anna Dimberg
Summary: This study demonstrates that the use of immunostimulatory CD40 antibodies in glioma models promotes the formation of tertiary lymphoid structures but does not improve survival and impairs the response to immune checkpoint blockade.
NATURE COMMUNICATIONS
(2021)
Review
Immunology
Tiarne van de Walle, Alessandra Vaccaro, Mohanraj Ramachandran, Ilkka Pietila, Magnus Essand, Anna Dimberg
Summary: Glioblastoma is an aggressive brain tumor with a low prevalence of tumor-reactive T cells, and recent data suggest that naive T cells may be activated within brain tumor-associated tertiary lymphoid structures. Promoting tertiary lymphoid structures could enhance priming of tumor antigen-targeted T cells and sensitize glioblastomas to cancer immunotherapy.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Nanoscience & Nanotechnology
Alessandra Iscaro, Christian Jones, Neil Forbes, Amina Mughal, Faith Nutter Howard, Haider Al Janabi, Secil Demiral, Yvonne Perrie, Magnus Essand, Aleksandra Weglarz, Luis J. Cruz, Claire E. Lewis, Munitta Muthana
Summary: This study demonstrates that encapsulating oncolytic adenovirus into CCL2-coated liposomes can effectively target tumors by recruiting circulating monocytes expressing CCR2. The nanomedicine approach significantly reduces tumor size and metastasis, providing a potential strategy for treating inaccessible tumors.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE
(2022)
Article
Biotechnology & Applied Microbiology
Mohiemen Anwar, Maja-Louise Arendt, Mohanraj Ramachandran, Anette Carlsson, Magnus Essand, Goran Akusjarvi, Ghasan Alusi, Daniel Oberg
Summary: This research describes a novel oncolytic adenovirus, Ixovex-1, which selectively replicates within cancer cells by modulating the level of expression of different E1B mRNA isoforms. The study demonstrates the characteristics and anti-tumor efficacy of Ixovex-1 in both in vitro and in vivo experiments, showing its superiority compared to other viruses with multiple deletions.
CANCER GENE THERAPY
(2022)
Article
Engineering, Biomedical
Chuan Jin, Jing Ma, Mohanraj Ramachandran, Di Yu, Magnus Essand
Summary: CAR T cells expressing NAP from Helicobacter pylori can trigger endogenous bystander T-cell responses against solid cancers, improving tumor growth and survival rates.
NATURE BIOMEDICAL ENGINEERING
(2022)
Review
Virology
Faith H. N. Howard, Amy Kwan, Natalie Winder, Amina Mughal, Cristal Collado-Rojas, Munitta Muthana
Summary: The number of emerging and re-emerging viral diseases has increased globally in recent decades. Host factors such as age, ethnicity, and underlying pathologies can affect the immune response and the outcome following viral infection.
Review
Virology
Natalie Winder, Sara Gohar, Munitta Muthana
Summary: Norovirus is a leading cause of gastroenteritis and responsible for a significant number of deaths annually. Outbreaks are common in small communities such as educational and care facilities. Nosocomial settings provide ideal conditions for transmission, particularly among immunocompromised individuals. The virus is transmitted through the fecal-oral route and can result in either asymptomatic cases or gastrointestinal disease. Mutations in the virus allow for the emergence of new resistant variants. The classification system divides Norovirus into 10 genogroups and 49 genotypes based on genetic sequencing.
Article
Multidisciplinary Sciences
Yung-Yi Chen, Krupali M. Patel, Rizwana Imran, Tarek Hassouna, Ezekwe Amirize, Abdulrazak Abdulsalam, Jonathan Bishop, Anita Slade, Maximina Ventura, Jeremy Yarrow, Janet M. Lord, Yvonne Wilson, Naiem S. Moiemen
Summary: This study aims to investigate the cellular kinetics in HTS after laser therapy, focusing on the association of scar reduction with the presence of senescent cells. The findings will provide a better understanding of the mechanisms involved in scar reduction with laser treatment and help improve treatment regimens for HTS patients.
Article
Immunology
Mohammed Ridha Moamin, Richard Allen, Steven Leslie Woods, Janet Elizabeth Brown, Harry Nunns, Anna Juncker-Jensen, Claire Elizabeth Lewis
Summary: This article investigates the distribution and interaction of immune cells in human TNBC and their response to NAC. The changes in certain cells may be associated with the risk of relapse. Additionally, the clustering of immune cells in perivascular areas may play a crucial role in the activation and function of T cells, and thus affect the efficacy of T cell-based immunotherapies.
FRONTIERS IN IMMUNOLOGY
(2023)
